Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib
Dacomitinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) and EGFR-activating mutations. Proton-pump inhibitors decreased dacomitinib exposure. This analysis summarizes the...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI AG
2024-01-01
|
| Colección: | Pharmaceutics |
| Materias: | |
| Acceso en línea: | https://www.mdpi.com/1999-4923/16/1/118 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|